L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis

• Status: Unknown status
• Trial end date: 2019-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aimed to investigate the efficacy and safety of Pegaspargase together with liposomal doxorubicin, etoposide and high dose methylprednisolone (L-DEP) as a salvage therapy for refractory Epstein Barr virus-induced hemophagocytic lymphohistiocytosis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Friendship Hospital
• Treatments: Asparaginase; Doxorubicin; Etoposide; Etoposide phosphate; Liposomal doxorubicin; Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Pegaspargase; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate

Criteria

Inclusion Criteria:

1. Patients were older than 14 years of age

2. Diagnosed as EBV-Hemophagocytic Lymphohistiocytosis (HLH)

3. Patients did not achieve at lease partial response after initial treatment including HLH-94 or DEP no less than 2 weeks

4. Informed consent

Exclusion Criteria:

1. Heart function above grade II (NYHA)

2. Accumulated dose of doxorubicin above 300mg/m2 or epirubicin above 450mg/m2

3. Pregnancy or lactating Women

4. Allergic to Pegaspargase, doxorubicin or etoposide

5. Active bleeding of the internal organs

6. uncontrollable infection

7. history of acute and chronic pancreatitis

8. Participate in other clinical research at the same time